# Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer

> **NCT00219271** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00219271
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219271, "Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00219271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*